Literature DB >> 25493261

Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report.

Samira M Sadowski1, Vladimir Neychev1, Candice Cottle-Delisle1, Roxanne Merkel1, Lily A Yang1, Martha M Quezado1, Richard Chang1, Electron Kebebew1.   

Abstract

Insulinomas are the most common cause of endogenous hyperinsulinemic hypoglycemia in non-diabetic adults. They are most often benign, small and difficult to localize with current imaging techniques. This is of high importance, as complete surgical resection is the only curative treatment. Anatomic imaging, (111)In-pentetreotide scan and (68)Gallium-DOTATATE positron emission tomography/computed tomography (PET/CT) were compared in a patient with insulinoma. (68)Gallium-DOTATATE PET/CT and selective arterial calcium stimulation localized the insulinoma. At surgery, a tumor in the anterior aspect of the pancreatic body was found which confirmed the preoperative localization, and a 2.1 cm tumor was enucleated, World Health Organization (WHO) grade I insulinoma. The patient remains euglycemic and free of symptoms at last follow up. In conclusion, (68)Gallium-DOTATATE PET/CT imaging may be a useful adjunct localizing study for insulinomas. It is a non-invasive preoperative localization study that could guide surgical exploration for successful therapy.

Entities:  

Keywords:  68Gallium-DOTATATE; Insulinoma; neuroendocrine tumor (NET); positron emission tomography (PET)

Year:  2014        PMID: 25493261      PMCID: PMC4244512          DOI: 10.3978/j.issn.2227-684X.2014.10.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  21 in total

1.  Well-differentiated pancreatic tumor/carcinoma: insulinoma.

Authors:  Wouter W de Herder; Bruno Niederle; Jean-Yves Scoazec; Stanislas Pauwels; Gunter Kloppel; Massimo Falconi; Dik J Kwekkeboom; Kjel Oberg; Barbro Eriksson; Bertram Wiedenmann; Guido Rindi; Dermot O'Toole; Diego Ferone
Journal:  Neuroendocrinology       Date:  2007-02-20       Impact factor: 4.914

2.  Forty-eight-hour fast: the diagnostic test for insulinoma.

Authors:  B Hirshberg; A Livi; D L Bartlett; S K Libutti; H R Alexander; J L Doppman; M C Skarulis; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors:  Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.

Authors:  Jigang Yang; Ying Kan; Benjamin H Ge; Leilei Yuan; Chunlin Li; Wenrui Zhao
Journal:  Acta Radiol       Date:  2013-08-08       Impact factor: 1.990

5.  Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium.

Authors:  J L Doppman; R Chang; D L Fraker; J A Norton; H R Alexander; D L Miller; E Collier; M C Skarulis; P Gorden
Journal:  Ann Intern Med       Date:  1995-08-15       Impact factor: 25.391

Review 6.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

7.  The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.

Authors:  Alexander R Haug; Ramona Cindea-Drimus; Christoph J Auernhammer; Martin Reincke; Björn Wängler; Christopher Uebleis; Gerwin P Schmidt; Burkhard Göke; Peter Bartenstein; Marcus Hacker
Journal:  J Nucl Med       Date:  2012-09-14       Impact factor: 10.057

8.  Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.

Authors:  Olof Eriksson; Irina Velikyan; Ram K Selvaraju; Fouad Kandeel; Lars Johansson; Gunnar Antoni; Barbro Eriksson; Jens Sörensen; Olle Korsgren
Journal:  J Clin Endocrinol Metab       Date:  2014-02-10       Impact factor: 5.958

9.  Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.

Authors:  J Bertherat; F Tenenbaum; K Perlemoine; C Videau; J L Alberini; B Richard; B Dousset; X Bertagna; J Epelbaum
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience.

Authors:  Jean-Marc Guettier; Anthony Kam; Richard Chang; Monica C Skarulis; Craig Cochran; H Richard Alexander; Steven K Libutti; James F Pingpank; Phillip Gorden
Journal:  J Clin Endocrinol Metab       Date:  2009-02-03       Impact factor: 5.958

View more
  4 in total

Review 1.  Endocrine neoplasms in familial syndromes of hyperparathyroidism.

Authors:  Yulong Li; William F Simonds
Journal:  Endocr Relat Cancer       Date:  2016-05-20       Impact factor: 5.678

2.  Insulinoma Due to Multiple Pancreatic Microadenoma Localized by Multimodal Imaging.

Authors:  Bruna Babic; Xavier Keutgen; Pavel Nockel; Markke Miettinen; Corina Millo; Peter Herscovitch; Dhaval Patel; Naris Nilubol; Craig Cochran; Phillip Gorden; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2016-08-09       Impact factor: 5.958

Review 3.  Exendin-4 analogs in insulinoma theranostics.

Authors:  Tom J P Jansen; Sanne A M van Lith; Marti Boss; Maarten Brom; Lieke Joosten; Martin Béhé; Mijke Buitinga; Martin Gotthardt
Journal:  J Labelled Comp Radiopharm       Date:  2019-08       Impact factor: 1.921

4.  Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.

Authors:  Natasha Alexander; Paula Marrano; Paul Thorner; Arlene Naranjo; Collin Van Ryn; Daniel Martinez; Vandana Batra; Libo Zhang; Meredith S Irwin; Sylvain Baruchel
Journal:  J Pediatr Hematol Oncol       Date:  2019-04       Impact factor: 1.289

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.